Fulcrum Therapeutics Inc. began to assemble its series B round in March, with the goal of advancing its lead program – a small molecule described as a double homeobox protein 4, or DUX4, inhibitor – through IND filing and into the clinic to treat facioscapulohumeral muscular dystrophy (FSHD). The rare genetic neuromuscular disease is characterized by progressive skeletal muscle weakness due to the death of muscle cells and tissue, leading four of five patients to lose their ability to walk by the time they reach early adulthood.